Leinco Technologies

Anti-Human CD52 (Alemtuzumab) - PE

Product Code:
 
LEI-LT204
Product Group:
 
Primary Antibodies
Host Type:
 
Human
Antibody Isotype:
 
Human IgG1κ
Antibody Clonality:
 
Monoclonal
Antibody Clone:
 
Campath-1H
Regulatory Status:
 
RUO
Target Species:
  • Cynomolgus Monkey
  • Human
  • Rhesus Macaque
Applications:
  • Flow Cytometry
  • Functional Study
  • Immunohistochemistry- Frozen Section (IHC-F)
  • Immunohistochemistry- Paraffin Embedded (IHC-P)
Shipping:
 
2-8°C
Storage:
 
This R-phycoerythrin (R-PE) conjugate is stable when stored at 2-8°C. Do not freeze.
 

No additional charges, what you see is what you pay! *

CodeSizePrice
LEI-LT204-50ug50 ug£265.00
Quantity:
Prices exclude any Taxes / VAT
How to order with us   Contact us
Stay in control of your spending. These prices have no additional charges, not even shipping!
* Rare exceptions are clearly labelled (only 0.14% of items!).
Multibuy discounts available! Contact us to find what you can save.
This product comes from: US.
Typical lead time: 14-21 working days.
Contact us for more accurate information.
  • Further Information
  • Show All

Further Information

Antigen Distribution:
CD52 is primarily expressed on the surface of mature lymphocytes. Additionally, CD52 is present on most lymphoid derived malignancies. However, variable expression on Myeloma cells should be noted.
Concentration:
0.2 mg/ml
Conjugate/Tag/Label:
R-phycoerythrin (PE)
Format:
This R-phycoerythrin (R-PE) conjugate is formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.4, 1% BSA and 0.09% sodium azide as a preservative.
Formulation:
This R-phycoerythrin (R-PE) conjugate is formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.4, 1% BSA and 0.09% sodium azide as a preservative.
Immunogen:
Human lymphocytes.
Long Description:
Clone Campath-1H is a monoclonal antibody that specifically binds to CD52, a protein present on the surface of mature lymphocytes. However, this protein is not present on the stem cells that generated these lymphocytes. Alemtuzumab is targets and destroys mature lymphocytes containing CD-52, and is used to treat chronic lymphocytic leukemia (CLL) and multiple sclerosis. Anti-Human CD52 (Alemtuzumab) utilizes the same variable regions from the therapeutic antibody Alemtuzumab making it ideal for research projects.
NCBI Gene:
1043
Target:
CD52